No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Truist Financial
Buy Rating Affirmed for Ultragenyx Pharmaceutical Based on Clinical Updates and Market Valuation Disconnect
Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality
DALLAS, May 14, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenera
Would Ultragenyx Pharmaceutical (NASDAQ:RARE) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor